In a patient who recently fell and sustained a head injury with a negative CT scan for intracranial hemorrhage, is it safe to restart clopidogrel (Plavix) 75 mg daily and apixaban (Eliquis) 5 mg twice daily immediately?

Restarting Anticoagulation After Head Trauma with Negative CT

Do not restart Plavix and Eliquis immediately after a negative head CT—wait at least 24-48 hours with close neurological monitoring, and consider delaying anticoagulation resumption for 2-7 days depending on bleeding and thrombotic risk assessment.

Key Decision Points

Immediate Post-Injury Period (First 24-48 Hours)

The 2023 ACEP guidelines emphasize that while delayed intracranial hemorrhage (ICH) after negative initial CT is rare in anticoagulated patients, the risk still exists and can be fatal 1. The evidence shows:

• Delayed ICH risk: 0.6% for warfarin patients (with 2 deaths reported), 0% for clopidogrel alone in the landmark Nishijima study 1
• For DOACs (like Eliquis): Pooled risk of delayed ICH is 2.43% (95% CI, 1.31-3.88%), though 86% of these bleeds had no clinical consequences 2
• Critical window: Most delayed hemorrhages occur within the first 24 hours

Timing for Resumption

The 2025 French guidelines provide the most specific framework 3:

For non-intracranial bleeding with negative CT:

• Resume therapeutic anticoagulation between Day 2 and Day 7 after assessing:
  • Bleeding risk (mechanism: traumatic vs spontaneous)
  • Thrombotic risk (indication for anticoagulation)
  • Whether hemostasis has been definitively achieved

The Plavix FDA label is explicit 4: "Resume Plavix as soon as hemostasis is achieved" after temporary discontinuation for bleeding risk.

The Eliquis FDA label states 5: "ELIQUIS should be restarted after the surgical or other procedures as soon as adequate hemostasis has been established."

Practical Algorithm

Step 1: Assess Injury Severity (First 24 Hours)

• GCS score: If 15 with no neurological symptoms → lower risk
• Mechanism: Ground-level fall vs high-impact trauma
• Symptoms: Loss of consciousness, amnesia, ongoing headache
• Concurrent medications: Dual antiplatelet therapy increases risk

Step 2: Observation Period

• Minimum 24 hours of neurological monitoring before considering restart
• Serial neurological exams (not necessarily repeat CT if patient remains neurologically stable) 1
• The evidence does NOT support routine repeat CT at 4-6 hours if patient is neurologically intact 6, 7

Step 3: Risk Stratification for Restart

HIGH thrombotic risk (restart earlier, Day 2-3):

• Recent proximal DVT/PE (within 1 month)
• Mechanical heart valve
• Recent stroke/TIA (within 3 months)
• High CHA₂DS₂-VASc score (≥5)

LOWER thrombotic risk (can wait Day 5-7):

• Atrial fibrillation with moderate CHA₂DS₂-VASc score
• Remote VTE history
• Primary prevention indication

Step 4: Restart Strategy

For Plavix (clopidogrel):

• Resume at 75 mg daily (no loading dose needed) 4
• Evidence shows clopidogrel alone had 0% delayed ICH in the ACEP guideline review 1

For Eliquis (apixaban):

• Resume at previous dose (typically 5 mg BID or 2.5 mg BID) 5
• Apixaban has comparable or lower ICH risk than aspirin in some analyses 8

Critical Caveats

Do NOT restart immediately if:

• Patient has ongoing neurological symptoms
• GCS < 15
• Patient is on dual therapy (anticoagulant + antiplatelet)—this significantly increases bleeding risk 1
• INR remains elevated (if previously on warfarin)
• High-impact mechanism with significant head trauma

Special Consideration for Dual Therapy

Your patient is on both Plavix AND Eliquis—this is dual antithrombotic therapy and carries substantially higher bleeding risk. Consider:

• Consulting cardiology/neurology about necessity of continuing both agents
• If both must be continued, extend observation period to at least 48-72 hours
• Consider whether one agent could be temporarily held while restarting the other

When to Consider IVC Filter

If patient has acute VTE (within 1 month) and cannot safely restart anticoagulation due to bleeding concerns, discuss removable IVC filter placement 3.

Bottom Line for Your Patient

Wait at least 48 hours before restarting either medication, with continuous neurological monitoring. If the patient remains neurologically stable at 48 hours with GCS 15 and no new symptoms, you can consider restarting medications on Day 2-3 if thrombotic risk is high, or Day 5-7 if thrombotic risk is moderate. The combination of both anticoagulant and antiplatelet therapy requires extra caution—strongly consider multidisciplinary discussion about whether both agents are truly necessary, and provide explicit return precautions about signs of delayed hemorrhage (severe headache, confusion, focal deficits, seizures).